Veradermics (MANE) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $115.07, +1.41% vs the prior close of $113.47.
- Volume 688.90K shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
MANE rises 1.4% to $115.07. Closed at $115.07, +1.41% vs the prior close of $113.47. Day range $111.05–$115.99, opened at $112.74.
MANE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — MANE rises 1.4% to $115.07
- Closed at $115.07, +1.41% vs the prior close of $113.47. Day range $111.05–$115.99, opened at $112.74.
- Volume was 688.90K shares, 0.9x its 50-day average of 756.44K.
- Price is +5.3% vs its 50-day average ($109.26).
- 52-week range $32.00–$136.72; today's close sits at 79% of that range, 15.8% below the 52-week high.
Oct 14, 2026 — MANE dips 2.4% to $113.47, 3 down days in a row
- Closed at $113.47, -2.40% vs the prior close of $116.26. Day range $112.62–$118.91, opened at $115.35.
- Volume was 484.60K shares, 0.6x its 50-day average of 780.80K.
- Price is +3.9% vs its 50-day average ($109.19).
- 52-week range $32.00–$136.72; today's close sits at 78% of that range, 17.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — MANE slides 5.0% to $116.26
- Closed at $116.26, -5.02% vs the prior close of $122.40. Day range $115.67–$122.27, opened at $121.17.
- Volume was 845.10K shares, 1.0x its 50-day average of 819.21K.
- Price is +6.6% vs its 50-day average ($109.06).
- 52-week range $32.00–$136.72; today's close sits at 80% of that range, 15.0% below the 52-week high.
Oct 12, 2026 — MANE slides 6.5% to $122.40
- Closed at $122.40, -6.49% vs the prior close of $130.90. Day range $120.57–$129.99, opened at $129.99.
- Volume was 991.40K shares, 1.2x its 50-day average of 817.75K.
- Price is +12.5% vs its 50-day average ($108.77).
- 52-week range $32.00–$136.72; today's close sits at 86% of that range, 10.5% below the 52-week high.
Oct 9, 2026 — MANE jumps 3.4% to $130.90, a 6-month high, 3 up days in a row
- Closed at $130.90, +3.37% vs the prior close of $126.63. Day range $123.02–$135.12, opened at $125.71.
- Volume was 1.11M shares, 1.4x its 50-day average of 809.16K.
- Price is +20.7% vs its 50-day average ($108.43).
- 52-week range $32.00–$136.72; today's close sits at 94% of that range, 4.3% below the 52-week high.
- That makes 3 straight gains.
Oct 8, 2026 — MANE jumps 14.1% to $126.63, a 3-month high on 4.7x normal volume
- Closed at $126.63, +14.13% vs the prior close of $110.95. Day range $110.56–$136.72, opened at $111.60.
- Volume was 3.49M shares, 4.7x its 50-day average of 748.31K — unusually heavy trading.
- Price is +17.4% vs its 50-day average ($107.90).
- 52-week range $32.00–$136.72; today's close sits at 90% of that range, 7.4% below the 52-week high.
Oct 7, 2026 — MANE rises 1.8% to $110.95
- Closed at $110.95, +1.83% vs the prior close of $108.96. Day range $108.84–$113.43, opened at $108.92.
- Volume was 655.10K shares, 0.9x its 50-day average of 754.98K.
- Price is +3.2% vs its 50-day average ($107.52).
- 52-week range $32.00–$131.24; today's close sits at 80% of that range, 15.5% below the 52-week high.
Oct 6, 2026 — MANE slides 8.3% to $108.96
- Closed at $108.96, -8.34% vs the prior close of $118.87. Day range $108.77–$119.29, opened at $119.29.
- Volume was 736.50K shares, 1.0x its 50-day average of 751.33K.
- Price is +1.3% vs its 50-day average ($107.54).
- 52-week range $32.00–$131.24; today's close sits at 78% of that range, 17.0% below the 52-week high.
Oct 5, 2026 — MANE rises 1.8% to $118.87
- Closed at $118.87, +1.81% vs the prior close of $116.76. Day range $114.80–$119.12, opened at $116.45.
- Volume was 536.20K shares, 0.7x its 50-day average of 751.27K.
- Price is +10.5% vs its 50-day average ($107.58).
- 52-week range $32.00–$131.24; today's close sits at 88% of that range, 9.4% below the 52-week high.
Oct 2, 2026 — MANE dips 0.4% to $116.76
- Closed at $116.76, -0.39% vs the prior close of $117.22. Day range $115.48–$120.85, opened at $120.26.
- Volume was 598.30K shares, 0.8x its 50-day average of 747.19K.
- Price is +8.7% vs its 50-day average ($107.40).
- 52-week range $32.00–$131.24; today's close sits at 85% of that range, 11.0% below the 52-week high.
MANE latest news & SEC filings
Every SEC filing by or about MANE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 21, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 21, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Averill Master Fund, Ltd. sold 690,601 shares at $107.25 (≈$74.07M) on Aug 19, 2026
- Averill Master Fund, Ltd. sold 59,399 shares at $107.25 (≈$6.37M) on Aug 19, 2026
- Montanova Capital, Llc sold 690,601 shares at $107.25 (≈$74.07M) on Aug 19, 2026
- Montanova Capital, Llc sold 59,399 shares at $107.25 (≈$6.37M) on Aug 19, 2026
- Averill Madison Master Fund, Ltd. sold 690,601 shares at $107.25 (≈$74.07M) on Aug 19, 2026
- Averill Madison Master Fund, Ltd. sold 59,399 shares at $107.25 (≈$6.37M) on Aug 19, 2026
- …plus 2 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 20, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Aug 19, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 19, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Durso Timothy August sold 161 shares at $111.28 (≈$17.92K) on Aug 17, 2026
- Durso Timothy August sold 7,918 shares at $106.71 (≈$844.93K) on Aug 17, 2026
- Durso Timothy August sold 16,306 shares at $107.52 (≈$1.75M) on Aug 17, 2026
- Durso Timothy August sold 16,767 shares at $108.38 (≈$1.82M) on Aug 17, 2026
- Durso Timothy August sold 2,348 shares at $109.34 (≈$256.73K) on Aug 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 14, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Aug 14, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$23.50M (prior year -$15.64M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.58 (prior year -$24.19) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 7, 2026 · Form S-1 — Registration statement (S-1)
Registration statement (S-1) — registering new shares, usually for an IPO or offering
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Things to know before you trade MANE
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2026, Apr 27, 2026, Mar 30, 2026. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.51% (largest 14.1%). That is a volatile stock.
- Liquidity: about 957.11K shares (≈$110.13M) trade per day on average.
- 52-week position: $115.07 vs a range of $32.00–$136.72 (79% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 21 sales; latest: Master Fund, Ltd. Averill sold 690,601 shares on Aug 19, 2026.
- Latest filings: 10-Q Aug 11, 2026; 8-K Aug 11, 2026; 8-K Jul 15, 2026.
- Listing: NYSE · industry: Pharmaceutical Preparations.
MANE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 112.74 | 115.99 | 111.05 | 115.07 | 688.90K |
| Oct 14, 2026 | 115.35 | 118.91 | 112.62 | 113.47 | 484.60K |
| Oct 13, 2026 | 121.17 | 122.27 | 115.67 | 116.26 | 845.10K |
| Oct 12, 2026 | 129.99 | 129.99 | 120.57 | 122.40 | 991.40K |
| Oct 9, 2026 | 125.71 | 135.12 | 123.02 | 130.90 | 1.11M |
| Oct 8, 2026 | 111.60 | 136.72 | 110.56 | 126.63 | 3.49M |
| Oct 7, 2026 | 108.92 | 113.43 | 108.84 | 110.95 | 655.10K |
| Oct 6, 2026 | 119.29 | 119.29 | 108.77 | 108.96 | 736.50K |
| Oct 5, 2026 | 116.45 | 119.12 | 114.80 | 118.87 | 536.20K |
| Oct 2, 2026 | 120.26 | 120.85 | 115.48 | 116.76 | 598.30K |
| Oct 1, 2026 | 121.23 | 123.83 | 116.04 | 117.22 | 659.80K |
| Sep 30, 2026 | 117.56 | 122.44 | 116.76 | 121.23 | 689.40K |
| Sep 29, 2026 | 115.34 | 118.94 | 112.03 | 117.82 | 481.70K |
| Sep 28, 2026 | 114.57 | 118.00 | 112.30 | 115.00 | 633.50K |
| Sep 25, 2026 | 116.00 | 118.15 | 113.88 | 116.57 | 613.60K |
| Sep 24, 2026 | 115.29 | 117.91 | 111.51 | 115.72 | 580.70K |
| Sep 23, 2026 | 118.11 | 118.74 | 110.60 | 115.78 | 753.80K |
| Sep 22, 2026 | 113.99 | 122.00 | 113.22 | 118.14 | 2.14M |
| Sep 21, 2026 | 107.44 | 113.24 | 105.40 | 112.80 | 583.60K |
| Sep 18, 2026 | 109.30 | 109.30 | 104.54 | 106.75 | 1.87M |
About Veradermics
Veradermics (MANE) is listed on the NYSE and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW HAVEN, CT. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1827635.
MANE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Madison Master Fund, Ltd. Averill | Director | Aug 21, 2026 |
| Master Fund, Ltd. Averill | Director | Aug 21, 2026 |
| John W Childs | Director | Aug 14, 2026 |
| Vlad Coric | Director | Feb 5, 2026 |
| Patrick G Enright | Director | Feb 5, 2026 |
| David Matthew Friedman | Director | Feb 5, 2026 |
| Jane M. Grant-Kels | Director | Feb 5, 2026 |
| Capital, Llc Montanova | See footnotes | Aug 21, 2026 |
| Katarina Pance | Director | Feb 5, 2026 |
| Capital Management, Llc Suvretta | See footnotes | May 5, 2026 |
| Reid Alexander Waldman | Chief Executive Officer | Aug 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Dominic Gabriel Carrano | Chief Financial Officer | Feb 5, 2026 |
| Timothy August Durso | Chief Technical Officer | Aug 18, 2026 |
| Michael V. Greco | General Counsel | Feb 5, 2026 |
| David Hollander | Chief R&D Officer | Sep 3, 2026 |
| Mark Neumann | Chief Commercial Officer | Feb 5, 2026 |
| Reid Alexander Waldman | Chief Executive Officer | Aug 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 19, 2026 | Master Fund, Ltd. Averill | Sale | 690,601 | $107.25 |
| Aug 19, 2026 | Master Fund, Ltd. Averill | Sale | 59,399 | $107.25 |
| Aug 19, 2026 | Capital, Llc Montanova | Sale | 690,601 | $107.25 |
| Aug 19, 2026 | Capital, Llc Montanova | Sale | 59,399 | $107.25 |
| Aug 19, 2026 | Madison Master Fund, Ltd. Averill | Sale | 690,601 | $107.25 |
| Aug 19, 2026 | Madison Master Fund, Ltd. Averill | Sale | 59,399 | $107.25 |
| Aug 19, 2026 | Aaron Cowen | Sale | 690,601 | $107.25 |
| Aug 19, 2026 | Aaron Cowen | Sale | 59,399 | $107.25 |
| Aug 17, 2026 | Reid Alexander Waldman | Sale | 11,527 | $106.72 |
| Aug 17, 2026 | Reid Alexander Waldman | Sale | 25,234 | $107.53 |
| Aug 17, 2026 | Reid Alexander Waldman | Sale | 27,490 | $108.45 |
| Aug 17, 2026 | Reid Alexander Waldman | Sale | 3,000 | $109.38 |
| Aug 17, 2026 | Reid Alexander Waldman | Sale | 249 | $111.28 |
| Aug 17, 2026 | Timothy August Durso | Sale | 161 | $111.28 |
| Aug 17, 2026 | Timothy August Durso | Sale | 7,918 | $106.71 |
MANE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-70.00M | -111.91 | $-71.60M |
| Dec 31, 2024 | — | $-26.49M | -37.05 | $-23.69M |
Latest balance sheet: total assets $825.74M, total liabilities $12.12M, cash $319.33M (as of Jun 30, 2026).
MANE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $108.95 |
| May 12, 2026 | 8-K Item 2.02 (results) | $103.90 |
| Apr 27, 2026 | 8-K Item 2.02 (results) | $100.10 |
| Mar 30, 2026 | 8-K Item 2.02 (results) | $60.85 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on MANE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.